MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Vericel Corporation DIO Ratio 2011-2026 | VCEL
Annual DIO Ratio Vericel Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 90.2 | 85.4 | 85.7 | 98.2 | 82.7 | 73.9 | 66.2 | 40.4 | 45.6 | 45 | 19 | 40.5 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 98.2 | 19 | 64.4 |
Quarterly DIO Ratio Vericel Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 89.1 | 93.1 | 96.4 | - | 86 | 80.8 | 76.3 | - | 80.8 | 83.5 | 98.7 | - | 57.3 | 46.2 | 100 | - | 95.7 | 84.2 | 77.5 | - | 87.2 | 98.6 | 74.4 | - | 66.7 | 68.9 | 54.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 100 | 46.2 | 80.8 |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Grifols, S.A.
GRFS
|
0.000171 | $ 8.24 | -0.12 % | $ 6.83 B |  Spain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
512 | - | - | $ 40.3 B |  USA |
 |
Midatech Pharma plc
MTP
|
40.6 | - | -18.52 % | $ 27.3 M |  Britain |
 |
AbbVie
ABBV
|
91.6 | $ 208.84 | -2.86 % | $ 369 B | USA |
 |
Acorda Therapeutics
ACOR
|
345 | - | -24.86 % | $ 820 K | USA |
 |
Aeterna Zentaris
AEZS
|
55.6 | - | 5.93 % | $ 314 M |  Canada |
 |
Agenus
AGEN
|
0.163 | $ 3.33 | -2.06 % | $ 99 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
275 | - | - | - |  Russia |
 |
Adaptive Biotechnologies Corporation
ADPT
|
46.7 | $ 14.81 | 2.63 % | $ 2.25 B | USA |
 |
Amgen
AMGN
|
200 | $ 347.94 | -1.51 % | $ 187 B | USA |
 |
ANI Pharmaceuticals
ANIP
|
181 | $ 74.21 | -2.3 % | $ 1.43 B | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
474 | $ 15.61 | 0.9 % | $ 2.1 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
70.7 | $ 1.41 | 2.17 % | $ 375 M | Britain |
 |
Aytu BioScience
AYTU
|
209 | $ 2.68 | 1.52 % | $ 16.8 M | USA |
 |
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B | Britain |
 |
BioCryst Pharmaceuticals
BCRX
|
892 | $ 9.02 | -3.84 % | $ 1.86 B | USA |
 |
Axon Enterprise
AXON
|
116 | $ 412.81 | -2.54 % | $ 31.3 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
43.5 | $ 318.85 | -3.01 % | $ 41.8 B | USA |